← Eichor
Condition: Subcutaneous Tumor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Subcutaneous Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AnovaOS Network Powered Patient Registry
Phase N/A · 1 location(s) · Anova Enterprises, Inc · NCT05013944To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Health
Phase 1 · 1 location(s) · Shenzhen Kexing Pharmaceutical Co., Ltd. · NCT07237464L19IL2/TNF in Patients With Basal Cell Carcinoma
Phase 2 · 18 location(s) · Philogen S.p.A. · NCT07227870Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Phase 1/Phase 2 · 1 location(s) · University of Maryland, Baltimore · NCT07075510A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M
Phase 3 · 42 location(s) · Merck Sharp & Dohme LLC · NCT07513376A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Phase 2/Phase 3 · 9 location(s) · UCB Biopharma SRL · NCT06055959Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NA · 9 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07095023Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Phase 1/Phase 2 · 2 location(s) · Starton Therapeutics, Inc · NCT06087653A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06505395Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer
NA · 1 location(s) · University Hospital, Montpellier · NCT06569706A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Ad
Phase 1 · 15 location(s) · TerSera Therapeutics LLC · NCT07310420A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Phase 1 · 31 location(s) · Daiichi Sankyo · NCT07015697Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Phase 1 · 11 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07260708Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/Phase 2 · 6 location(s) · Simcha IL-18, Inc. · NCT04787042D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Phase 1/Phase 2 · 1 location(s) · Darell Bigner · NCT05734560A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/Phase 2 · 37 location(s) · Dren Bio · NCT05475925Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07404605A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell
Phase 1 · 14 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07179679Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Phase 1 · 31 location(s) · Amgen · NCT06598306Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) o
Phase 4 · 11 location(s) · AbbVie · NCT07044687Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-M
Phase 2 · 248 location(s) · SWOG Cancer Research Network · NCT06116682A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Recept
Phase 2 · 110 location(s) · Janssen Research & Development, LLC · NCT05498428A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Lo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04239157A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in
Phase N/A · 91 location(s) · Hoffmann-La Roche · NCT07284121Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Phase 2 · 1 location(s) · West Virginia University · NCT07222579A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, f
Phase 2 · 202 location(s) · Janssen Research & Development, LLC · NCT06667076A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Phase 1 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07275242Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07451912Role of Genetic Factors in the Development of Lung Disease
Phase N/A · 2 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00001532A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT05978141
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.